mProX™ Human FCGR3A Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

FCGR3A, also known as CD16a, is a gene that has been studied in various medical contexts. In a study on lung squamous cell carcinoma (LUSC), researchers constructed a prognostic model and miRNA-mRNA regulatory network using data from the cancer genome atlas (TCGA) database. They identified FCGR3A as one of the hub-targeted mRNAs in the protein-protein interaction (PPI) network, which provided insights into the molecular pathogenesis of LUSC and potential applications in clinical diagnosis and treatment. Another study focused on gene copy number estimation and found that FCGR3A showed a higher concordance compared to other methods, indicating its potential use in this context. In a study on pemphigus vulgaris and pemphigus foliaceus, FCGR3A alleles/genotypes were found to be differentially expressed, suggesting a potential role in the pathogenesis of these diseases. Finally, in a study on diabetic retinopathy (DR), FCGR3A was identified as one of the hub genes associated with immune infiltration in the retina of DR patients, highlighting its potential as a diagnostic marker for this condition. Overall, FCGR3A has been implicated in various diseases and has potential applications in prognosis, gene copy number estimation, autoimmune disorders, and retinal diseases.